Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $18.80 Consensus PT from Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month […]
